blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3218372

EP3218372 - MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  26.03.2021
Database last updated on 03.10.2024
FormerThe patent has been granted
Status updated on  17.04.2020
FormerGrant of patent is intended
Status updated on  17.12.2019
FormerExamination is in progress
Status updated on  18.11.2019
FormerGrant of patent is intended
Status updated on  17.07.2019
FormerExamination is in progress
Status updated on  03.08.2018
FormerRequest for examination was made
Status updated on  18.08.2017
FormerThe international publication has been made
Status updated on  19.05.2017
Most recent event   Tooltip15.07.2022Lapse of the patent in a contracting state
New state(s): BE		published on 17.08.2022  [2022/33]
Applicant(s)For all designated states
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
[2017/38]
Inventor(s)01 / MAZZAFERRO, Rocco
Boehringer Ingelheim GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim Am Rhein / DE
02 / FERRARA, Marco
Boehringer Ingelheim GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim Am Rhein / DE
03 / GIOVANNINI, Riccardo
Boehringer Ingelheim GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim Am Rhein / DE
04 / LINGARD, Iain
Boehringer Ingelheim GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim Am Rhein / DE
05 / RUDOLF, Klaus
Boehringer Ingelheim GmbH
Corporate Patents
Binger Strasse 173
55216 Ingelheim Am Rhein / DE
 [2017/38]
Representative(s)Simon, Elke Anna Maria, et al
Boehringer Ingelheim GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
[2017/38]
Application number, filing date15793840.812.11.2015
[2017/38]
WO2015EP76440
Priority number, dateEP2014019318514.11.2014         Original published format: EP 14193185
[2017/38]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016075240
Date:19.05.2016
Language:EN
[2016/20]
Type: A1 Application with search report 
No.:EP3218372
Date:20.09.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 19.05.2016 takes the place of the publication of the European patent application.
[2017/38]
Type: B1 Patent specification 
No.:EP3218372
Date:20.05.2020
Language:EN
[2020/21]
Search report(s)International search report - published on:EP19.05.2016
ClassificationIPC:C07D413/12, C07D471/04, C07D265/30, C07D267/10, A61P29/00, A61K31/4353
[2017/38]
CPC:
C07D267/10 (EP,CN,EA,KR,US); C07D413/12 (EP,CN,EA,KR,US); A61K31/5377 (EP,EA,US);
A61K31/4375 (KR); A61K31/535 (KR); A61K31/55 (EP,EA,US);
A61K31/553 (KR); A61P19/02 (EP); A61P25/04 (EP);
A61P29/00 (EP); A61P43/00 (EP); C07D265/30 (EP,CN,EA,KR,US);
C07D471/04 (EP,CN,EA,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/38]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:MORPHOLIN- UND 1,4-OXAZEPANAMIDE ALS SOMATOSTATINREZEPTOR-SUBTYP-4(SSTR4)-AGONISTEN[2017/38]
English:MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS[2017/38]
French:AMIDES DE MORPHOLINE ET DE 1,4-OXAZÉPANE UTILISÉS EN TANT QU'AGONISTES DU SOUS-TYPE 4 DU RÉCEPTEUR DE LA SOMATOSTATINE (SSTR4)[2017/38]
Entry into regional phase14.06.2017National basic fee paid 
14.06.2017Designation fee(s) paid 
14.06.2017Examination fee paid 
Examination procedure19.05.2017Date on which the examining division has become responsible
14.06.2017Examination requested  [2017/38]
20.12.2017Amendment by applicant (claims and/or description)
03.08.2018Despatch of a communication from the examining division (Time limit: M02)
04.10.2018Reply to a communication from the examining division
18.07.2019Communication of intention to grant the patent
15.11.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
18.12.2019Communication of intention to grant the patent
08.04.2020Fee for grant paid
08.04.2020Fee for publishing/printing paid
08.04.2020Receipt of the translation of the claim(s)
Opposition(s)23.02.2021No opposition filed within time limit [2021/17]
Fees paidRenewal fee
30.11.2017Renewal fee patent year 03
30.11.2018Renewal fee patent year 04
02.12.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU12.11.2015
AL20.05.2020
AT20.05.2020
CY20.05.2020
CZ20.05.2020
DK20.05.2020
EE20.05.2020
ES20.05.2020
FI20.05.2020
HR20.05.2020
IT20.05.2020
LT20.05.2020
LV20.05.2020
MC20.05.2020
MK20.05.2020
MT20.05.2020
NL20.05.2020
PL20.05.2020
RO20.05.2020
RS20.05.2020
SE20.05.2020
SI20.05.2020
SK20.05.2020
SM20.05.2020
TR20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
IE12.11.2020
LU12.11.2020
BE30.11.2020
CH30.11.2020
LI30.11.2020
[2022/33]
Former [2022/32]HU12.11.2015
AL20.05.2020
AT20.05.2020
CY20.05.2020
CZ20.05.2020
DK20.05.2020
EE20.05.2020
ES20.05.2020
FI20.05.2020
HR20.05.2020
IT20.05.2020
LT20.05.2020
LV20.05.2020
MC20.05.2020
MK20.05.2020
MT20.05.2020
NL20.05.2020
PL20.05.2020
RO20.05.2020
RS20.05.2020
SE20.05.2020
SI20.05.2020
SK20.05.2020
SM20.05.2020
TR20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
IE12.11.2020
LU12.11.2020
CH30.11.2020
LI30.11.2020
Former [2022/27]HU12.11.2015
AL20.05.2020
AT20.05.2020
CY20.05.2020
CZ20.05.2020
DK20.05.2020
EE20.05.2020
ES20.05.2020
FI20.05.2020
HR20.05.2020
IT20.05.2020
LT20.05.2020
LV20.05.2020
MC20.05.2020
MT20.05.2020
NL20.05.2020
PL20.05.2020
RO20.05.2020
RS20.05.2020
SE20.05.2020
SI20.05.2020
SK20.05.2020
SM20.05.2020
TR20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
IE12.11.2020
LU12.11.2020
CH30.11.2020
LI30.11.2020
Former [2021/46]AL20.05.2020
AT20.05.2020
CZ20.05.2020
DK20.05.2020
EE20.05.2020
ES20.05.2020
FI20.05.2020
HR20.05.2020
IT20.05.2020
LT20.05.2020
LV20.05.2020
MC20.05.2020
NL20.05.2020
PL20.05.2020
RO20.05.2020
RS20.05.2020
SE20.05.2020
SI20.05.2020
SK20.05.2020
SM20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
IE12.11.2020
LU12.11.2020
CH30.11.2020
LI30.11.2020
Former [2021/37]AL20.05.2020
AT20.05.2020
CZ20.05.2020
DK20.05.2020
EE20.05.2020
ES20.05.2020
FI20.05.2020
HR20.05.2020
IT20.05.2020
LT20.05.2020
LV20.05.2020
MC20.05.2020
NL20.05.2020
PL20.05.2020
RO20.05.2020
RS20.05.2020
SE20.05.2020
SI20.05.2020
SK20.05.2020
SM20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
LU12.11.2020
CH30.11.2020
LI30.11.2020
Former [2021/33]AL20.05.2020
AT20.05.2020
CZ20.05.2020
DK20.05.2020
EE20.05.2020
ES20.05.2020
FI20.05.2020
HR20.05.2020
IT20.05.2020
LT20.05.2020
LV20.05.2020
MC20.05.2020
NL20.05.2020
PL20.05.2020
RO20.05.2020
RS20.05.2020
SE20.05.2020
SI20.05.2020
SK20.05.2020
SM20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
LU12.11.2020
Former [2021/31]AL20.05.2020
AT20.05.2020
CZ20.05.2020
DK20.05.2020
EE20.05.2020
ES20.05.2020
FI20.05.2020
HR20.05.2020
IT20.05.2020
LT20.05.2020
LV20.05.2020
MC20.05.2020
NL20.05.2020
PL20.05.2020
RO20.05.2020
RS20.05.2020
SE20.05.2020
SI20.05.2020
SK20.05.2020
SM20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2021/24]AL20.05.2020
AT20.05.2020
CZ20.05.2020
DK20.05.2020
EE20.05.2020
ES20.05.2020
FI20.05.2020
HR20.05.2020
IT20.05.2020
LT20.05.2020
LV20.05.2020
NL20.05.2020
PL20.05.2020
RO20.05.2020
RS20.05.2020
SE20.05.2020
SI20.05.2020
SK20.05.2020
SM20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2021/10]AL20.05.2020
AT20.05.2020
CZ20.05.2020
DK20.05.2020
EE20.05.2020
ES20.05.2020
FI20.05.2020
HR20.05.2020
IT20.05.2020
LT20.05.2020
LV20.05.2020
NL20.05.2020
PL20.05.2020
RO20.05.2020
RS20.05.2020
SE20.05.2020
SK20.05.2020
SM20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2021/09]AL20.05.2020
AT20.05.2020
CZ20.05.2020
DK20.05.2020
EE20.05.2020
ES20.05.2020
FI20.05.2020
HR20.05.2020
IT20.05.2020
LT20.05.2020
LV20.05.2020
NL20.05.2020
RO20.05.2020
RS20.05.2020
SE20.05.2020
SM20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2021/08]AL20.05.2020
DK20.05.2020
ES20.05.2020
FI20.05.2020
HR20.05.2020
LT20.05.2020
LV20.05.2020
NL20.05.2020
RO20.05.2020
RS20.05.2020
SE20.05.2020
SM20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2021/04]AL20.05.2020
FI20.05.2020
HR20.05.2020
LT20.05.2020
LV20.05.2020
NL20.05.2020
RS20.05.2020
SE20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2021/01]FI20.05.2020
HR20.05.2020
LT20.05.2020
LV20.05.2020
RS20.05.2020
SE20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2020/51]FI20.05.2020
HR20.05.2020
LT20.05.2020
LV20.05.2020
RS20.05.2020
SE20.05.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2020/50]FI20.05.2020
HR20.05.2020
LT20.05.2020
LV20.05.2020
SE20.05.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2020/48]FI20.05.2020
LT20.05.2020
SE20.05.2020
NO20.08.2020
IS20.09.2020
PT21.09.2020
Former [2020/47]LT20.05.2020
NO20.08.2020
IS20.09.2020
Former [2020/46]IS20.09.2020
Cited inInternational search[AD]WO2010059922  (LIGAND PHARM INC [US], et al) [AD] 1-16 * page 22, paragraph 125; claim 1 *;
 [A]  - CRIDER A MICHAEL ET AL, "Somatostatin sst4 ligands: chemistry and pharmacology", MINI REVIEWS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBL, NL, (20070301), vol. 7, no. 3, ISSN 1389-5575, pages 213 - 220, XP009129242 [A] 1-16 * the whole document *
by applicantWO2010059922
 WO2012120476
    - CRIDER, A, MINI REV. MED. CHEM., (2002), vol. 7, page 213
    - J. AM. CHEM. SOC., (1998), vol. 120, pages 1368 - 1373
    - BERGE, S.M. ET AL., J. PHARM. SCI., (1977), vol. 66, pages 1 - 19
    - J. ORG. CHEM., (1992), vol. 57, pages 4521 - 452
    - CHOU; TALALAY, ADV. ENZYME REGUL, (1984), vol. 22, pages 27 - 55
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.